Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $8.8450 and last traded at $8.8450, with a volume of 188 shares. The stock had previously closed at $8.1201.
Oxford BioMedica Stock Performance
The company has a quick ratio of 1.67, a current ratio of 1.89 and a debt-to-equity ratio of 3.08. The stock’s 50 day simple moving average is $8.37 and its two-hundred day simple moving average is $7.11.
Oxford BioMedica Company Profile
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Featured Articles
- Five stocks we like better than Oxford BioMedica
- Buy this $2 Gold Stock Before January 1, 2026
- Executive Order 14330: Trump’s Biggest Yet
- Do not delete, read immediately
- BNZI Posts Record Q3 Revenue – See What’s Driving It.
- If You Keep Cash In A U.S. Bank Account… Read This NOW
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
